Skip to content

Amgen AMGN Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Pfizer logo
PfizerPFE
$2.18B+23.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$23.65M-13.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%

Valuation

See full
Market cap$190.42B+22.4%
Enterprise value$247.18B+16.4%
P/E24.4×-1.8×
P/S5.1×+0.6×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Calculated from Amgen’s reported figures.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's free cash flow?
Amgen (AMGN) reported free cash flow of $1.48B in Q1 2026.
How has Amgen's free cash flow changed year-over-year?
Amgen's free cash flow increased by 50.7% year-over-year, from $980M to $1.48B.
What is the long-term trend for Amgen's free cash flow?
Over 4 years (2021 to 2025), Amgen's free cash flow has grown at a -0.8% compound annual growth rate (CAGR), from $8.38B to $8.1B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.